162 related articles for article (PubMed ID: 34552007)
1. Growth Inhibition and Induction of Innate Immune Signaling of Chondrosarcomas with Epigenetic Inhibitors.
Sheikh TN; Chen X; Xu X; McGuire JT; Ingham M; Lu C; Schwartz GK
Mol Cancer Ther; 2021 Dec; 20(12):2362-2371. PubMed ID: 34552007
[TBL] [Abstract][Full Text] [Related]
2. Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine.
Ahrens TD; Timme S; Hoeppner J; Ostendorp J; Hembach S; Follo M; Hopt UT; Werner M; Busch H; Boerries M; Lassmann S
Epigenetics; 2015; 10(5):431-45. PubMed ID: 25923331
[TBL] [Abstract][Full Text] [Related]
3. Suberoylanilide hydroxamic acid (SAHA) induces apoptosis or autophagy-associated cell death in chondrosarcoma cell lines.
Yamamoto S; Tanaka K; Sakimura R; Okada T; Nakamura T; Li Y; Takasaki M; Nakabeppu Y; Iwamoto Y
Anticancer Res; 2008; 28(3A):1585-91. PubMed ID: 18630516
[TBL] [Abstract][Full Text] [Related]
4. Functional profiling of receptor tyrosine kinases and downstream signaling in human chondrosarcomas identifies pathways for rational targeted therapy.
Zhang YX; van Oosterwijk JG; Sicinska E; Moss S; Remillard SP; van Wezel T; Bühnemann C; Hassan AB; Demetri GD; Bovée JV; Wagner AJ
Clin Cancer Res; 2013 Jul; 19(14):3796-807. PubMed ID: 23714727
[TBL] [Abstract][Full Text] [Related]
5. A histone deacetylase inhibitor enhances expression of genes inhibiting Wnt pathway and augments activity of DNA demethylation reagent against nonsmall-cell lung cancer.
Shieh JM; Tang YA; Hu FH; Huang WJ; Wang YJ; Jen J; Liao SY; Lu YH; Yeh YL; Wang TW; Lin P; Wang YC
Int J Cancer; 2017 May; 140(10):2375-2386. PubMed ID: 28233309
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of anti-viral responses in intestinal epithelial cells by epigenetic modifying drugs is mediated by a reduction in viral pattern recognition receptor expression and activity.
Hennessy C; O'Connell S; Egan LJ; McKernan DP
Immunopharmacol Immunotoxicol; 2019 Oct; 41(5):527-537. PubMed ID: 31505962
[No Abstract] [Full Text] [Related]
7. Epigenetic combination therapy as a tumor-selective treatment approach for hepatocellular carcinoma.
Venturelli S; Armeanu S; Pathil A; Hsieh CJ; Weiss TS; Vonthein R; Wehrmann M; Gregor M; Lauer UM; Bitzer M
Cancer; 2007 May; 109(10):2132-41. PubMed ID: 17407132
[TBL] [Abstract][Full Text] [Related]
8. Epigenetics and miRNA as predictive markers and targets for lung cancer chemotherapy.
El-Awady RA; Hersi F; Al-Tunaiji H; Saleh EM; Abdel-Wahab AH; Al Homssi A; Suhail M; El-Serafi A; Al-Tel T
Cancer Biol Ther; 2015; 16(7):1056-70. PubMed ID: 25962089
[TBL] [Abstract][Full Text] [Related]
9. Beyond the Influence of
Venneker S; Kruisselbrink AB; Baranski Z; Palubeckaite I; Briaire-de Bruijn IH; Oosting J; French PJ; Danen EHJ; Bovée JVMG
Cancers (Basel); 2020 Nov; 12(12):. PubMed ID: 33266275
[TBL] [Abstract][Full Text] [Related]
10. The effects of histone deacetylase inhibitors on the induction of differentiation in chondrosarcoma cells.
Sakimura R; Tanaka K; Yamamoto S; Matsunobu T; Li X; Hanada M; Okada T; Nakamura T; Li Y; Iwamoto Y
Clin Cancer Res; 2007 Jan; 13(1):275-82. PubMed ID: 17200366
[TBL] [Abstract][Full Text] [Related]
11. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic silencing of SFRP5 promotes the metastasis and invasion of chondrosarcoma by expression inhibition and Wnt signaling pathway activation.
Sheng W; Zhang ZC; Shi DY; Wang BC; Wu Q; Shao ZW; Yang SH; He TC; Liu JX
Chem Biol Interact; 2018 Dec; 296():1-8. PubMed ID: 30125549
[TBL] [Abstract][Full Text] [Related]
13. [Epigenetic mechanisms and alcohol use disorders: a potential therapeutic target].
Legastelois R; Jeanblanc J; Vilpoux C; Bourguet E; Naassila M
Biol Aujourdhui; 2017; 211(1):83-91. PubMed ID: 28682229
[TBL] [Abstract][Full Text] [Related]
14. Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for non-small-cell lung cancer cells.
Takashina T; Kinoshita I; Kikuchi J; Shimizu Y; Sakakibara-Konishi J; Oizumi S; Nishimura M; Dosaka-Akita H
Cancer Sci; 2016 Jul; 107(7):955-62. PubMed ID: 27116120
[TBL] [Abstract][Full Text] [Related]
15. Assessment of new HDAC inhibitors for immunotherapy of malignant pleural mesothelioma.
Bensaid D; Blondy T; Deshayes S; Dehame V; Bertrand P; Grégoire M; Errami M; Blanquart C
Clin Epigenetics; 2018; 10():79. PubMed ID: 29946373
[TBL] [Abstract][Full Text] [Related]
16. Bifunctional HDAC and DNMT inhibitor induces viral mimicry activates the innate immune response in triple-negative breast cancer.
Fan W; Li W; Li L; Qin M; Mao C; Yuan Z; Wang P; Chu B; Jiang Y
Eur J Pharm Sci; 2024 Jun; 197():106767. PubMed ID: 38636781
[TBL] [Abstract][Full Text] [Related]
17. Curcumol Controls Choriocarcinoma Stem-Like Cells Self-Renewal via Repression of DNA Methyltransferase (DNMT)- and Histone Deacetylase (HDAC)-Mediated Epigenetic Regulation.
Peng Z; Zhou W; Zhang C; Liu H; Zhang Y
Med Sci Monit; 2018 Jan; 24():461-472. PubMed ID: 29363667
[TBL] [Abstract][Full Text] [Related]
18. Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy.
Chen MY; Liao WS; Lu Z; Bornmann WG; Hennessey V; Washington MN; Rosner GL; Yu Y; Ahmed AA; Bast RC
Cancer; 2011 Oct; 117(19):4424-38. PubMed ID: 21491416
[TBL] [Abstract][Full Text] [Related]
19. Identification of coexistence of DNA methylation and H3K27me3 specifically in cancer cells as a promising target for epigenetic therapy.
Takeshima H; Wakabayashi M; Hattori N; Yamashita S; Ushijima T
Carcinogenesis; 2015 Feb; 36(2):192-201. PubMed ID: 25477340
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic upregulation of Bak by ZBP-89 inhibits the growth of hepatocellular carcinoma.
Ye CG; Chen GG; Ho RLK; Merchant JL; He ML; Lai PBS
Biochim Biophys Acta; 2013 Dec; 1833(12):2970-2979. PubMed ID: 23954442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
